These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 23754707

  • 1. Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome.
    Hughes MC, Wright A, Barbour A, Thomas J, Smithers BM, Green AC, Khosrotehrani K.
    Int J Cancer; 2013 Dec 15; 133(12):3000-7. PubMed ID: 23754707
    [Abstract] [Full Text] [Related]

  • 2. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.
    van der Ploeg AP, Haydu LE, Spillane AJ, Scolyer RA, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Thompson JF.
    Ann Surg Oncol; 2014 Sep 15; 21(9):3108-16. PubMed ID: 24802907
    [Abstract] [Full Text] [Related]

  • 3. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site.
    Prens SP, van der Ploeg AP, van Akkooi AC, van Montfort CA, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C.
    Ann Surg Oncol; 2011 Dec 15; 18(13):3586-92. PubMed ID: 21611857
    [Abstract] [Full Text] [Related]

  • 4. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
    Lee CC, Faries MB, Wanek LA, Morton DL.
    J Clin Oncol; 2008 Feb 01; 26(4):535-41. PubMed ID: 18235114
    [Abstract] [Full Text] [Related]

  • 5. Melanoma without a detectable primary site with metastases to lymph nodes.
    Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pieñkowski A, Salamacha M, Michej W, Trepka S, Bylina E, Ruka W.
    Dermatol Surg; 2010 Jun 01; 36(6):868-76. PubMed ID: 20482725
    [Abstract] [Full Text] [Related]

  • 6. Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis.
    Glover AR, Allan CP, Wilkinson MJ, Strauss DC, Thomas JM, Hayes AJ.
    Br J Surg; 2014 Jun 01; 101(7):811-9. PubMed ID: 24752717
    [Abstract] [Full Text] [Related]

  • 7. Survival after lymphadenectomy of nodal metastases from melanoma of unknown primary site.
    Gullestad HP, Ryder T, Goscinski M.
    J Plast Surg Hand Surg; 2023 Jun 01; 57(1-6):109-114. PubMed ID: 34878354
    [Abstract] [Full Text] [Related]

  • 8. Melanoma of unknown primary origin: a population-based study in the Netherlands.
    de Waal AC, Aben KK, van Rossum MM, Kiemeney LA.
    Eur J Cancer; 2013 Feb 01; 49(3):676-83. PubMed ID: 23031553
    [Abstract] [Full Text] [Related]

  • 9. Metastatic melanoma to lymph nodes in patients with unknown primary sites.
    Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI.
    Cancer; 2006 May 01; 106(9):2012-20. PubMed ID: 16568458
    [Abstract] [Full Text] [Related]

  • 10. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI, Rutkowski P, Michej W.
    Ann Surg Oncol; 2008 Aug 01; 15(8):2223-34. PubMed ID: 18506535
    [Abstract] [Full Text] [Related]

  • 11. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD, Ranieri J, Evdokimow DZ, Logan T, Chuang TY, Johnson CS, Jung SH, Wenck S, Coleman JJ.
    Plast Reconstr Surg; 2003 Aug 01; 112(2):486-97. PubMed ID: 12900606
    [Abstract] [Full Text] [Related]

  • 12. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
    Zdzienicki M, Rutkowski P, Nowecki ZI, van Akkooi AC, Michej W, Dziewirski W, Świtaj T, Pieńkowski A, Sałamacha M, Bylina E, Eggermont AM.
    Eur J Surg Oncol; 2013 Mar 01; 39(3):304-10. PubMed ID: 23298828
    [Abstract] [Full Text] [Related]

  • 13. Sentinel-node biopsy or nodal observation in melanoma.
    Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ, MSLT Group.
    N Engl J Med; 2006 Sep 28; 355(13):1307-17. PubMed ID: 17005948
    [Abstract] [Full Text] [Related]

  • 14. [Giant metastatic melanoma arising from an unknown primary site].
    Ørndrup MH, Crewe B, Stolle LB.
    Ugeskr Laeger; 2014 Jan 20; 176(4A):V08130487. PubMed ID: 25347250
    [Abstract] [Full Text] [Related]

  • 15. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma.
    Hughes TM, A'Hern RP, Thomas JM.
    Br J Surg; 2000 Jul 20; 87(7):892-901. PubMed ID: 10931025
    [Abstract] [Full Text] [Related]

  • 16. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
    Mozzillo N, Pasquali S, Santinami M, Testori A, Di Marzo M, Crispo A, Patuzzo R, Verrecchia F, Botti G, Montella M, Rossi CR, Caracò C.
    Eur J Surg Oncol; 2015 Jul 20; 41(7):823-9. PubMed ID: 25800935
    [Abstract] [Full Text] [Related]

  • 17. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, Hayward NK.
    Eur J Cancer; 2014 Oct 20; 50(15):2668-76. PubMed ID: 25070294
    [Abstract] [Full Text] [Related]

  • 18. Improved survival for stage IV melanoma from an unknown primary site.
    Lee CC, Faries MB, Wanek LA, Morton DL.
    J Clin Oncol; 2009 Jul 20; 27(21):3489-95. PubMed ID: 19451446
    [Abstract] [Full Text] [Related]

  • 19. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
    Rossi CR, Mocellin S, Pasquali S, Pilati P, Nitti D.
    Ann Surg Oncol; 2008 Jan 20; 15(1):310-5. PubMed ID: 17987346
    [Abstract] [Full Text] [Related]

  • 20. Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients.
    Crookes TR, Scolyer RA, Lo S, Drummond M, Spillane AJ.
    Ann Surg Oncol; 2017 May 20; 24(5):1378-1385. PubMed ID: 28130620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.